Skip to main content

Table 2 Baseline patient characteristics among stage III patients comprising the retrospective cohort

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

  Vaccine No Adjuvant  
  N = 67 N = 123  
  N(%)/Mean(SD) N(%)/Mean(SD) P-Value
Age 56.00 (13.44) 60.05 (16.44) 0.086
Sex    0.2854
 Female 31 (46.27) 47 (38.21)  
 Male 36 (53.73) 76 (61.79)  
Thicknessa 3.12 (4.43) 4.18 (4.46) 0.009
Ulceration    0.3511
 Present 23 (34.33) 52 (42.28)  
 Absent 32 (47.76) 57 (46.34)  
 Undetermined 12 (17.91) 14 (11.38)  
AJCC Stage    0.0082
 IIIA 15 (22.39) 48 (39.02)  
 IIIB 26 (38.81) 51 (41.46)  
 IIIC 26 (38.81) 24 (19.51)  
Histologic Subtype    0.0435
 Nodular 17 (25.37) 52 (42.28)  
 Superficial Spreading 12 (17.91) 26 (21.14)  
 Other 6 (8.96) 13 (10.57)  
 Undetermined 32 (47.76) 32 (26.02)  
Other Adjuvant Treatment   
 GM-CSF 6 (8.96) Not Applicable  
 Interferon 6 (8.96)  
 Isolated Limb Infusion 3 (4.48)  
 Radiation 22 (32.84)  
  1. amissing values for thickness: vaccine: 10; no adjuvant: 13
  2. athickness not normally-distributed, log-transformed for statistical test